Bristol-Myers Squibb Co (FRA:BRM) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BRM Bristol-Myers Squibb Co FRA:BRM
71 GF Score
Price €54.81
GF Value €48.67
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Bristol-Myers Squibb Co  (FRA:BRM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Related Terms


Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.39 4.68 2.94 3.13 2.41

Bristol-Myers Squibb Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.13 2.02 2.40 2.69 2.55

FRA:BRM vs PFE, GILD, AMGN: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio falls into.


FRA:BRM
71GF Score
Bristol-Myers Squibb Co FRA:BRM
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Bristol-Myers Squibb Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.452/333.9520*333.9520
=5.452

Current CPI (Jun. 2026) = 333.9520.

Bristol-Myers Squibb Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.627 241.428 3.634
201612 2.894 241.432 4.003
201703 2.768 243.801 3.792
201706 2.833 244.955 3.862
201709 2.721 246.819 3.682
201712 2.831 246.524 3.835
201803 2.576 249.554 3.447
201806 2.926 251.989 3.878
201809 2.991 252.439 3.957
201812 3.198 251.233 4.251
201903 3.185 254.202 4.184
201906 3.410 256.143 4.446
201909 3.306 256.759 4.300
201912 3.741 256.974 4.862
202003 4.334 258.115 5.607
202006 4.064 257.797 5.265
202009 3.940 260.280 5.055
202012 4.122 260.474 5.285
202103 4.059 264.877 5.118
202106 4.314 271.696 5.303
202109 4.396 274.310 5.352
202112 4.725 278.802 5.660
202203 4.798 287.504 5.573
202206 5.190 296.311 5.849
202209 5.185 296.808 5.834
202212 5.268 296.797 5.927
202303 5.001 301.836 5.533
202306 4.907 305.109 5.371
202309 4.884 307.789 5.299
202312 5.251 306.746 5.717
202403 5.404 312.332 5.778
202406 5.586 314.175 5.938
202409 5.330 315.301 5.645
202412 5.680 315.605 6.010
202503 5.217 319.799 5.448
202506 5.311 322.561 5.499
202509 5.129 324.800 5.274
202512 5.263 324.054 5.424
202603 4.797 330.213 4.851
202606 5.452 333.952 5.452

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Bristol-Myers Squibb Co (FRA:BRM) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of €54.81 is trading 12.6% above its estimated GF Value™ of €48.67. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for FRA:BRM:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €48.67 vs. price of €54.81 (12.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the FRA:BRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
71GF Score

Get the complete analysis for FRA:BRM

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€54.81
Price
€48.67
GF Value